Biotech faces setbacks after Incyte's experimental cancer drug fails testing - Technical.ly Delaware

Business

Apr. 9, 2018 7:28 am

Biotech faces setbacks after Incyte’s experimental cancer drug fails testing

After a promising start, the Wilmington biotech company announced Friday that its epacadostat trial did not improve patient outcomes.

The results sent ripples across the biotech industry.

(Photo by Flickr user Bill Dickinson, used under a Creative Commons license)

Wilmington-based Incyte’s promising cancer drug, epacadostat, failed in trial that paired it with Merck’s drug Keytruda — a setback for the Wilmington biotech company that caused a dramatic 18 percent drop in its shares Friday.

In a chain reaction, other biotech companies including NewLink Genetics Corp. in Ames, Iowa, and Corvus Pharmaceuticals Inc. in Burlingame, California, also saw their stocks fall.

The Wall Street Journal reported:

Incyte’s drug, epacadostat, was previously viewed as one of the more promising of the next generation of cancer drugs designed to work by harnessing the patients’ own immune systems to destroy tumor cells.

Merck, Bristol-Myers Squibb Co. and other companies sell older types of immunotherapies that have improved treatment for certain cancers including the skin cancer melanoma and lung cancer. The market for these drugs is booming: Merck’s global Keytruda sales more than doubled to $3.8 billion last year.

But they don’t work for every patient, so companies have been racing to test whether combining older immunotherapies with other drugs could further improve patient survival.

Although promising in early trials, it was found in a larger trial launched in 2016 that the combination of epacadostat and Keytruda did not improve outcomes in test patients.

Last summer, an AstraZeneca study testing two PLC immunotherapies for lung cancer failed, calling into question the effectiveness of previously promising combination drug therapy.

Read the full story -30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

Delaware science institute nabs big-name collabo with Cali’s Zymergen

Hatch House Wilmington is done, and Steve Boerner is trying something new

The best way to cancel a workshop no one signed up for

SPONSORED

Delaware

Join our Technical.ly Match beta, an opt-in alternative to recruiting

Wilmington, DE

CSC

Business Analyst

Apply Now
Wilmington DE

JPMorgan Chase & Co.

Hadoop, Big Data Associate

Apply Now
Wilmington DE

JPMorgan Chase & Co.

VP, Kafka Software Engineer

Apply Now

Here is everything Ben Rapkin learned from the life and death of his startup

Why this UD entrepreneur’s Christmas sweater ecommerce shop failed

After shutting down his startup, UD grad Ben Rapkin reflects on what he’s learned

SPONSORED

Delaware

Win up to $360,000 in funding at the WeWork Creator Awards

Wilmington DE

JPMorgan Chase & Co.

BI Developer

Apply Now
Kennett Square, PA

Chatham Financial

Software Developer in Test

Apply Now
Kennett Square, PA

Chatham Financial

User Experience Designer

Apply Now

Sign-up for daily news updates from Technical.ly Delaware

Do NOT follow this link or you will be banned from the site!